tirzepatide treatment roseville ca Injections in Sacramento, Tirzepatide: Dual Action, Lasting Impact

doi: 10.1016/bs.vh.2022.01.011

STEP 1 (published in NEJM 2021) demonstrated that participants receiving semaglutide 2.4 mg experienced mean reductions in total cholesterol of approximately 5-7%, LDL-C reductions of 5-8%, and triglyceride reductions of 12-15% from baseline

Key properties: Does not increase cortisol important for avoiding stress hormone elevation Does not increase prolactin no hormonal disruption Minimal ghrelin-like hunger suitable when appetite stimulation is unwanted Dose-dependent GH release predictable, linear response This selectivity makes Ipamorelin the go-to choice when a clean GH pulse is the primary goal without metabolic side effects

For Canadians dealing with or at risk for non-alcoholic fatty liver disease (NAFLD), this dual action on liver fat represents one of the most compelling reasons to consider the combination

Baseline nausea, reflux, or inflammatory bowel conditions amplify GI side effect risk